Corxel Pharmaceuticals has raised $287m to fund its suite of cardiometabolic assets, signifying that investor appetite for ...

Daiichi Sankyo and AstraZeneca’s Enhertu has received approval from China’s NMPA for adult patients with locally advanced or ...

As more drugs go subcutaneous, CEO of Phillips Medisize, Tony Bedford, believes that high-dose biologics will become a prevalent choice for drugmakers.

AstraZeneca has agreed to buy AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031.

Staying ahead of pharma supply challenges rests on anticipatory pillars and does not require reinventing the wheel, says ...

Speaking at the World Economic Forum in Davos, Donald Trump said tariffs helped fix the long-time drug pricing scam in the US ...

Novartis has announced that the FDA has granted a breakthrough therapy designation to ianalumab, a treatment for Sjögren’s ...

GSK's RAPT Therapeutics acquisition will strengthen the former's immunology pipeline – specifically its offerings for food ...

The key element of the agreement is confirmation that UK pharmaceutical exports to the US will face a preferential tariff ...

Bristol Myers Squibb (BMS) has entered into an agreement with Microsoft to advance AI-driven early lung cancer detection.

Pfizer exits ViiV Healthcare with a $1.89bn payout, while GSK retains its majority stake amid the shareholder shake-up.